Vladimir Yutkin1, Hashim U Ahmed2, Ian Donaldson2, Neil McCartan2, Khurram Siddiqui1, Mark Emberton2, Joseph L Chin3. 1. Division of Urology, Department of Surgery, University of Western Ontario, London, Ontario, Canada. 2. Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Division of Surgery and Interventional Science, University College London, United Kingdom. 3. Division of Urology, Department of Surgery, University of Western Ontario, London, Ontario, Canada. Electronic address: joseph.chin@lhsc.on.ca.
Abstract
OBJECTIVE: To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer. PATIENTS AND METHODS: Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed. RESULTS: Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population. CONCLUSION: In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.
OBJECTIVE: To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer. PATIENTS AND METHODS: Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed. RESULTS: Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population. CONCLUSION: In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.
Authors: Michele Billia; Khurram M Siddiqui; Susanne Chan; Fan Li; Ali Al-Zahrani; Jose A Gomez; Joseph L Chin Journal: Can Urol Assoc J Date: 2016 Nov-Dec Impact factor: 1.862
Authors: Khurram M Siddiqui; Michele Billia; Andrew Williams; Ali Alzahrani; Joseph L Chin Journal: Can Urol Assoc J Date: 2015 Sep-Oct Impact factor: 1.862
Authors: Thomas Leroy; Thomas Lacornerie; Emilie Bogart; Philippe Nickers; Eric Lartigau; David Pasquier Journal: Radiat Oncol Date: 2017-06-09 Impact factor: 3.481
Authors: Willemien van den Bos; Berrend G Muller; Daniel M de Bruin; Andre Luis de Castro Abreu; Christian Chaussy; Jonathan A Coleman; Antonio Finelli; Inderbir S Gill; Mitchell E Gross; Sjoerd F M Jenniskens; Frank Kahmann; M Pilar Laguna-Pes; Ardeshir R Rastinehad; Lucy A Simmons; Tullio Sulser; Arnauld Villers; John F Ward; Jean J M C H de la Rosette Journal: Urol Oncol Date: 2015-07-29 Impact factor: 2.954
Authors: Shawn Dason; Nathan C Wong; Christopher B Allard; Jen Hoogenes; William Orovan; Bobby Shayegan Journal: Int Braz J Urol Date: 2018 Mar-Apr Impact factor: 1.541